Skip to main content

Market Overview

Raymond James: CVS A Strong Buy Despite Pricing Headwinds

Raymond James: CVS A Strong Buy Despite Pricing Headwinds

CVS Health Corp (NYSE: CVS) stock was down Tuesday following news of a pricing disagreement with Walmart Inc (NYSE: WMT), which will leave its pharmacy benefits network — but the broader pricing headwinds the company faces shouldn’t deter investors, Raymond James said.

The Analyst

Analyst John Ransom reiterated a Strong Buy rating on CVS with a $90 price target. 

The Thesis

CVS management recently gave a presentation in which it said it was seeing continued reimbursement pressure in its retail pharmacy business while getting less relief from falling generic drug costs, Ransom said in a Monday note. 

On the pharmacy benefits management side, higher guaranteed rebates and lower-than-expected brand inflation were also seen as headwinds by the company.

Raymond James is making more conservative assumptions and lowered its 2019 earnings per share estimate by 30 cents to $7.40.

Investors have already accounted for lower earnings per share, and with the stock’s 20-percent drop from recent highs, it remains a strong buying opportunity, the analyst said. 

A Break With Walmart

The Raymond James note was issued before CVS announced later Tuesday that Walmart would no longer participate in the network of providers where customers of some of CVS’s Caremark pharmacy benefit programs can have their prescriptions filled. CVS said in a press release that it was balking at Walmart's request for higher reimbursements.

"While we have enjoyed a long relationship with Walmart as a low-cost provider in our broad national networks, based on our commitment to helping our clients and consumers manage rising pharmacy costs, we simply could not agree to their recent demands for an increase in reimbursement,” Derica Rice, president of CVS Caremark — CVS Health's pharmacy benefit management business — said in the statement.

The move won't have a huge impact, as fewer than 5 percent of the CVS Caremark members in affected programs fill their prescriptions at Walmart, CVS said. 

Price Action

CVS shares were down 2.45 percent at $63.74 at the close Tuesday.

Related Links:

Analysts Love CVS Health Shares Following Aetna Deal

Vaccine Business The Gateway To Drug Stores Providing Profitable Primary Healthcare

Photo via Wikimedia. 

Latest Ratings for CVS

Apr 2021Truist SecuritiesMaintainsBuy
Apr 2021Morgan StanleyMaintainsOverweight
Mar 2021GuggenheimDowngradesBuyNeutral

View More Analyst Ratings for CVS
View the Latest Analyst Ratings


Related Articles (CVS)

View Comments and Join the Discussion!

Posted-In: John Ransom Raymond JamesAnalyst Color Health Care Price Target Reiteration Analyst Ratings General Best of Benzinga

Latest Ratings

SKXMorgan StanleyUpgrades56.0
INTUWolfe ResearchInitiates Coverage On475.0
PLANWolfe ResearchInitiates Coverage On72.0
AALRaymond JamesUpgrades
PCTYWolfe ResearchInitiates Coverage On200.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at